Making preclinical models more human-like: 10 new 3D cell or mouse models meant to better mimic human organ function or disease
About us
BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The BioCentury Show on YouTube www.biocenturyyoutube.com Subscribe to the "BioCentury This Week" podcast www.biocenturypodcast.com
- Website
-
http://www.biocentury.com
External link for BioCentury Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, CA
- Type
- Privately Held
- Specialties
- Biotechnology, Pharmaceutical, Healthcare Ecosystem, Drug Development, Business Strategy, Policy, Regulatory, Finance, Deal Making, Venture Capital, and biopharma
Locations
-
Primary
Redwood City, CA 94065, US
Employees at BioCentury Inc.
Updates
-
"We're really building the program this year around reinventing your strategy...looking at what China #biotechs need to do to reinvent their global strategy and what Western #biopharmas and #investors need to do to reinvent their China strategy." Joshua Berlin, Head of Business Development at BioCentury Inc., joined the #BioCenturyThisWeek podcast to discuss the upcoming #BioCenturyChinaSummit in Shanghai, where biopharma CEOs and investors will gather to network, partner and debate about cross-border opportunities. Listen to the full podcast: https://lnkd.in/gUZnRteV View the agenda, list of speakers and register at https://lnkd.in/gv4D7Mtu Can't make it to Shanghai? Register for a digital pass to access streaming content and two days of virtual partnering.
-
Causal biology, ultrarare drugs and big pharma moves: the latest episode of the #BioCenturyThisWeek podcast covers: ➤ Strategies to prove causal links in disease ➤ Stealth’s FDA bid for Barth syndrome ➤ Lundbeck’s $2.6B acquisition of Longboard. Tune in on your favorite podcast platform: https://lnkd.in/gcbtZrvR
-
Stealth's advisory committee meeting showcases power of patient voice: Following a dramatic advisory committee meeting on elamipretide from Stealth BioTherapeutics, FDA finds itself in a familiar, uncomfortable place. Advocates of patients with a devastating ultrarare condition with no approved treatments are demanding that the agency overlook flawed data to approve the drug, while the agency's reviewers are adamant the data do not support approval. Read Washington Editor Steve Usdin's analysis: https://lnkd.in/g9pxK7HF #ultrararediseases #FDA
-
A BioCentury Inc. Q&A with the NIH's Daniel Reich on the future of drug development for progressive #MS and how recent data could impact therapeutic strategies for treating #neuroinflammation in other #neurodegenerative settings
A new chapter for
biocentury.com
-
As the #bearmarket drags on, biotech CEOs are focused on reinventing their global strategies to extend their cash runway. In this #BioCenturyChinaSummit roundtable in Shanghai, China #biotech CEOs discuss lessons learned on the road to globalization. Session Chair: Joan (Huaqiong) Shen, NeuShen Therapeutics Panelists: zhaoyu jin, FutureGen Biopharmaceutical Maha Radhakrishnan, Sofinnova Investments Stella (Yibin) Shi, Rona Therapeutics Chengbin Wu, EpimAb Biotherapeutics, Inc. John Zhu, Duality Biologics View the full agenda and who you will meet: https://lnkd.in/gmZjHaCG Register and learn more at https://lnkd.in/gv4D7Mtu.
-
Discovery through perturbation: taking causality into your own hands. A company's experimental setup and scale shape the type of AI it uses and questions it can ask
Discovery through perturbation: taking causality into your own hands
biocentury.com
-
We cannot continue to ignore the heterogeneity in ALS. The tools exist, it’s time to embrace them. Long-read sequencing is just one of the force-multipliers at hand, argues PAACS Invest Co-Chair Masha Stromme in a BioCentury Guest Commentary
We cannot continue to ignore heterogeneity in ALS
biocentury.com
-
BioCentury Washington Editor Steve Usdin joined BioIndustry Association (BIA)'s Steve Bates OBE FMedSci and Goodwin's Matt Wetzel for a panel discussion on the impact of US politics on the biotech sector, including insights into the #InflationReductionAct and the #Biosecure bill. Hear how these developments could shape the future for UK biotech: https://lnkd.in/ddHGmAJC
BIA Webinar: Developments in US politics for UK biotech
https://www.youtube.com/
-
On this week's #BioCenturyThisWeek podcast: ➤ Stephen Hansen discusses why buysiders and bankers believe biotech is primed for growth after three years of a bear market. ➤ Steve Usdin critiques the FDA's planned reforms for advisory committees, calling for more impactful changes, and shares insights from CMS’s anti-amyloid decision. ➤ Joshua Berlin previews the upcoming #BioCenturyChinaSummit in Shanghai, which will focus on reinventing China strategies. Tune in on your favorite podcast platform: https://lnkd.in/gcbtZrvR